71 related articles for article (PubMed ID: 21409952)
1. From patient to mouse to therapy: role of the neuropeptide pacap in platelet function and formation.
Freson K
Verh K Acad Geneeskd Belg; 2010; 72(5-6):239-51. PubMed ID: 21409952
[TBL] [Abstract][Full Text] [Related]
2. PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications.
Freson K; Peeters K; De Vos R; Wittevrongel C; Thys C; Hoylaerts MF; Vermylen J; Van Geet C
Blood; 2008 Feb; 111(4):1885-93. PubMed ID: 18000164
[TBL] [Abstract][Full Text] [Related]
3. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation.
Freson K; Hashimoto H; Thys C; Wittevrongel C; Danloy S; Morita Y; Shintani N; Tomiyama Y; Vermylen J; Hoylaerts MF; Baba A; Van Geet C
J Clin Invest; 2004 Mar; 113(6):905-12. PubMed ID: 15067323
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis.
Peeters K; Loyen S; Van Kerckhoven S; Stoffels K; Hoylaerts MF; Van Geet C; Freson K
Br J Haematol; 2010 Oct; 151(1):54-61. PubMed ID: 20735399
[TBL] [Abstract][Full Text] [Related]
5. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
6. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
10. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
11. Role of VIP and PACAP in islet function.
Winzell MS; Ahrén B
Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA
Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463
[TBL] [Abstract][Full Text] [Related]
13. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.
Vaudry D; Falluel-Morel A; Bourgault S; Basille M; Burel D; Wurtz O; Fournier A; Chow BK; Hashimoto H; Galas L; Vaudry H
Pharmacol Rev; 2009 Sep; 61(3):283-357. PubMed ID: 19805477
[TBL] [Abstract][Full Text] [Related]
15. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
16. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development.
Basille M; Vaudry D; Coulouarn Y; Jegou S; Lihrmann I; Fournier A; Vaudry H; Gonzalez B
J Comp Neurol; 2000 Oct; 425(4):495-509. PubMed ID: 10975876
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in the brain.
Shioda S
Kaibogaku Zasshi; 2000 Dec; 75(6):487-507. PubMed ID: 11197592
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK.
Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH
Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696
[TBL] [Abstract][Full Text] [Related]
20. Differentiation induces pituitary adenylate cyclase-activating polypeptide receptor expression in PC-12 cells.
Cavallaro S; D'Agata V; Guardabasso V; Travali S; Stivala F; Canonico PL
Mol Pharmacol; 1995 Jul; 48(1):56-62. PubMed ID: 7623775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
